(Q33877888)

29 July 2017

1 reference

title

Tamoxifen for the prevention of breast cancer. (English)

1 reference

29 July 2017

1 reference

Fisher B

1

1 reference

29 July 2017

Powles TJ

series ordinal

2

1 reference

29 July 2017

Pritchard KJ

series ordinal

3

1 reference

29 July 2017

language of work or name

1 reference

1 January 2000

1 reference

European Journal of Cancer

29 July 2017

1 reference

29 July 2017

36

1 reference

29 July 2017

142-150

1 reference

29 July 2017

2

1 reference

Tamoxifen in advanced breast cancer

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Highlights of the NSABP Breast Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Is tamoxifen effective in prevention of breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900269-5

7 January 2021

10.1016/S0959-8049(99)00269-5

Identifiers

DOI

1 reference

29 July 2017

1 reference